Pharmaceutical and Medicine Manufacturing
Industry Group (3254)
2024-Q2: $6.58T MX, Gross Domestic Product
Jan-Jun 2024: US$446M, Foreign Direct Investment
In the second quarter of 2024 the gross domestic product was $6.58T MX, 5.06% more than the previous quarter.
According to data from the Economic Census 2019, total gross production was $189B MX. The states with the highest total gross production were Ciudad de México ($67.8B MX) and Estado de México ($38.3B MX).
For its part, total income reached $192B MX in 2019, being the states with the highest income Ciudad de México ($71.9B MX) and Estado de México ($40.1B MX).
Economic activities are related if they require similar knowledge or inputs. In 2014 in Pharmaceutical and Medicine Manufacturing the states with the highest affinity were Nuevo León (0.8), Querétaro (0.75), Ciudad de México (0.72), Jalisco (0.7), and Chihuahua (0.62).
Production
#permalink to sectionGross Domestic Product
#permalink to sectionGross domestic product 2024-Q2: $6.58T MX
Gross Domestic Product 2023: $6.37T MX
* Data displayed corresponds to the sector Manufacturing since the information at lower levels of disaggregation is not available.
In the second quarter of 2024, Manufacturing recorded a gross domestic product of $6.58T MX, evidencing an increase of 5.06% compared to the previous quarter and an increase of 2.27% compared to the same period of the previous year.
* Current values, at current prices, base year 2013. Excludes taxes on products.
Production Indicators by State
#permalink to sectionAccording to data from the Economic Census 2019, 837 economic units were totaled in Pharmaceutical and Medicine Manufacturing, highlighting Ciudad de México (236), Jalisco (141), and Estado de México (86).
Total gross production was $189B MX. The states with the highest total gross production were Ciudad de México ($67.8B MX) and Estado de México ($38.3B MX).
Total income reached $192B MX in 2019, being the states with the highest income Ciudad de México ($71.9B MX) and Estado de México ($40.1B MX).
* It is recommended to consider the values as approximations of the real value because some records have been anonymized due to confidentiality principles.
Production Indicators by Municipality
#permalink to sectionAccording to dato from Economic Census 2014, Pharmaceutical and Medicine Manufacturing had a total of 1,611 economic units and the municipalities with the highest number of economic units were Guadalajara (168), Zapopan (159), and Benito Juárez (120)
Total income eached $427B MX and the municipalities with the highest income were Toluca ($49.2B MX), Coyoacán ($45.5B MX), and Guadalajara ($40.9B MX).
Total expenditures were $350B MX and the municipalities with the highest expenditures were Toluca ($39.9B MX), Coyoacán ($32.7B MX), and Guadalajara ($31.8B MX).
On the other hand, in 2014 there were 143994 employees dependent on economic units and the municipalities with the highest number of employees were Coyoacán (23.4k), Guadalajara (18.7k), and Naucalpan de Juárez (9.79k).
* Any inconsistency between the data at the state and municipal level is due to the anonymization methodologies applied to the data, also municipalities not shown in the visualization have been anonymized.
Economic Units
#permalink to sectionThe visualization shows the number of economic units in Pharmaceutical and Medicine Manufacturing according to the number of employees.
According to DENUE data published in May 2024, 0 companies with 0 to 10 employees were registered (equal number of companies as the previous period). In the same period, 0 companies with 11 to 50 employees were registered (equal number of companies as the previous period).
0 companies with 51 to 100 employees were registered in 2024 (equal number of companies as the previous period). Likewise, 0 companies with more than 101 employees were registered (equal number of companies as the previous period).
Source National Statistical Directory of Economic Units (DENUE)
Investment
#permalink to sectionForeign Direct Investment (FDI)
#permalink to section- US$446M, FDI Jan-Jun 2024
- US$16B, FDI Jan-1999 to Jun-2024
In the period January to June 2024, FDI from Pharmaceutical and Medicine Manufacturing was US$446M, distributed in reinvestment of earnings (US$501M), equity Capital (US$0), and inter-company debts (-US$55.1M).
Since January 1999 to June 2024, the accumulated amount of FDI in Pharmaceutical and Medicine Manufacturing was US$16B, distributed in reinvestment of earnings (US$7.26B), equity Capital (US$6.02B), and inter-company debts (US$2.72B).
* Confidential data is not shown in the chart (see information icon in the section).
Foreign Direct Investment (FDI) by State
#permalink to sectionPeriod Jan-Jun 2024: US$0
Period Jan-1999 to Jun-2024: US$8.06B, Mexico City is the main receiving state
No FDI is recorded in the period January to June, 2024
Historically (from January 1999 to June2024) the states that have received the highest FDI are Mexico City (US$8.06B), Estado de México (US$2.54B), and Chihuahua (US$1.4B).
* Information download does not contain confidential data.
Foreign Direct Investment (FDI) Origin
#permalink to sectionPeriodo Jan-Jun 2024: ---, US$0
Main investing country between Jan-1999 and Jun-2024: United States, US$6.86B
No FDI is recorded in the period January to June of 2024.
Historically (from January 1999 to June de 2024) the countries that contributed the most to FDI were Germany (US$201M), Switzerland (US$152M), and United States (US$39.4M).
* Information download does not contain confidential data.
Specialization and Opportunity
#permalink to sectionThe states with the highest degree of development opportunity in Pharmaceutical and Medicine Manufacturing according to Relatedness were Chihuahua (0.62), Baja California (0.61), and Coahuila de Zaragoza (0.6). The Relatedness measures the distance between an industry and the current industrial composition in each state. The presented entities register a level of specialization lower than one unit (RCA <1).